1. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER). Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2017.
2. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER). Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. 1997.
3. USP 41 chapter <1088> In vitro and in vivo evaluation of dosage forms, in United States Pharmacopeia, U.S.P.C. Inc., Editor. 2018.
4. Gillespie WR. Convolution-based approaches for in vivo-in vitro correlation modeling. In: Young D, Devane JG, Butler J, editors. In vitro-in vivo correlations. Boston: Springer US; 1997. p. 53–65.
5. Wagner JG. Method for estimating rate constants for absorption, metabolism, and elimination from urinary excretion data. J Pharm Sci. 1967;56(4):489–94.